Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
BNT162b2 mRNA vaccine
COVID-19
IgA
SARS-CoV-2
Saliva
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
07
06
2022
revised:
21
12
2022
accepted:
23
12
2022
pubmed:
12
1
2023
medline:
15
2
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
To date, only a few studies reported data regarding the development of mucosal immune response after the BNT162b2-booster vaccination. Samples of both serum and saliva of 50 healthcare workers were collected at the day of the booster dose (T3) and after two weeks (T4). Anti-S1-protein IgG and IgA antibody titres and the neutralizing antibodies against the Wuhan wild-type Receptor-Binding Domain in both serum and saliva were measured by quantitative and competitive ELISA, respectively. Data were compared with those recorded after the primary vaccination cycle (T2). Neutralizing antibodies against the variants of concern were measured in those individuals with anti-Wuhan neutralizing antibodies in their saliva. After eight months from the second dose, IgG decreased in both serum (T2 The BNT162b2-booster vaccination elicits a strong systemic immune response but fails in activating an effective mucosal immunity against the Omicron BA.1 variant. This work was funded by the Department of Medicine and Surgery, University of Insubria, and supported by Fondazione Umberto Veronesi (COVID-19 Insieme per la ricerca di tutti, 2020), Italy.
Sections du résumé
BACKGROUND
BACKGROUND
To date, only a few studies reported data regarding the development of mucosal immune response after the BNT162b2-booster vaccination.
METHODS
METHODS
Samples of both serum and saliva of 50 healthcare workers were collected at the day of the booster dose (T3) and after two weeks (T4). Anti-S1-protein IgG and IgA antibody titres and the neutralizing antibodies against the Wuhan wild-type Receptor-Binding Domain in both serum and saliva were measured by quantitative and competitive ELISA, respectively. Data were compared with those recorded after the primary vaccination cycle (T2). Neutralizing antibodies against the variants of concern were measured in those individuals with anti-Wuhan neutralizing antibodies in their saliva.
FINDINGS
RESULTS
After eight months from the second dose, IgG decreased in both serum (T2
INTERPRETATION
CONCLUSIONS
The BNT162b2-booster vaccination elicits a strong systemic immune response but fails in activating an effective mucosal immunity against the Omicron BA.1 variant.
FUNDING
BACKGROUND
This work was funded by the Department of Medicine and Surgery, University of Insubria, and supported by Fondazione Umberto Veronesi (COVID-19 Insieme per la ricerca di tutti, 2020), Italy.
Identifiants
pubmed: 36628844
pii: S2352-3964(22)00617-X
doi: 10.1016/j.ebiom.2022.104435
pmc: PMC9828819
pii:
doi:
Substances chimiques
BNT162 Vaccine
0
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
Immunoglobulin A
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104435Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests None to declare.